Cytovia.png
CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)
April 07, 2020 09:03 ET | Cytovia Therapeutics
NEW YORK and AUSTIN, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer and...
Cytovia.png
Hebrew University to Collaborate with Cytovia Therapeutics
March 18, 2020 09:00 ET | Cytovia Therapeutics
NEW YORK and JERUSALEM, March 18, 2020 (GLOBE NEWSWIRE) -- Yissum, the technology transfer company of The Hebrew University of Jerusalem and Cytovia Therapeutics, Inc, a biopharmaceutical company...
Cytovia.png
CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics
January 09, 2020 08:00 ET | Cytovia Therapeutics
NEW YORK, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The New York Stem Cell Foundation (NYSCF) Research Institute today announced a partnership with Cytovia Therapeutics Inc. (Cytovia) to develop new disease...
Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy
January 06, 2020 08:00 ET | Cytovia Therapeutics
SAN FRANCISCO and NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, a biopharmaceutical company, and the University of California, San Francisco (UCSF) announced today that they have...